IQVIA Genomic Research Solutions
Data landscaping and integrated evidence planning
Secondary
data first
Prospective data collection
NLP
Precision oncology
Privacy to support genomic data
Biomarker patient recruitment
Sequencing
and bioinformatics
Hover to learn more
Data landscaping and integrated evidence planning
A broad search for appropriate data sources from our global catalog of >3,000 data sources (many exclusive to IQVIA)
Thorough assessment of clinical-genomic data available globally for effective, holistic evidence planning needs including discovery, regulatory, and market access
A rigorous approach covering both data quality and suitability, as well as operational readiness of data sources
Robust integrated evidence planning including internal stakeholder alignment
HEOR & RWE projects and discovery
KAIROS biobanking solutions
•
•
•
•
Secondary data first
Avoid expense and timeline impact of unnecessary primary data generation
Secondary data assets include 1 billion+ non-identified patient records
Contracts & processes in place with data partners for speed to value
Global data with local expertise
•
•
•
•
Prospective data collection
Established real-world research networks for rapid study starts
Access to global high-quality real-world data to support hybrid study designs
Deep understanding of regulator and payer needs to ensure effective study design and appropriate data quality
•
•
•
Sequencing and bioinformatics
Comprehensive genomic services for discovery, translational medicine, clinical development, and companion diagnostics
Full service multi-omic laboratory and analytical capabilities
90+ bioinformaticians and bioinformatics software developers
Global Lab locations including USA, UK and China
•
•
•
•
HEOR & RWE projects and discovery
Global personnel with local expertise to support HEOR & RWE for both payer evidence and regulatory needs
Blended teams of bioinformaticians, statisticians, data scientist, medical doctors, geneticists, disease experts & others to maximize probability of success
Proven effective results from a large number of paid-for client projects (including 150+ publications)
•
•
•
Biomarker patient recruitment
Identify hard-to-find patient populations, e.g., having specific genetic marker within an indication, specific lab test result, rare disease diagnosis
Identified data to contact patients directly, identified or de-identified data to contact physicians, who then contact patients
Technology and integrated patient recruitment process to ensure patients are evaluated and enrolled
•
•
•
Privacy to support genomic data
Inherent identifying nature of genomic sequence data addressed using a novel methodology to anonymize genomic information at the variant level
Anonymized genomic data can be linked to clinical data from other sources to provide a more complete patient profile, all while protecting patient privacy
Approach provides comprehensive genomic data privacy protection while still enabling a broad range of analytic techniques to advance research
•
•
•
NLP
Award-winning IQVIA natural language processing software that enables systematic, comprehensive identification, normalization and extraction of key concepts, topics and themes from unstructured text
Efficient generation of phenotype data from free text in EMR records, and rapid, effective genotype-phenotype annotations
Mapping data from structured and unstructured sources to enable integration with downstream databases and applications
•
•
•
KAIROS biobanking solutions
Broad-ranging tools for extensive documentation of biospecimens throughout their entire lifecycle per recognized gold standards (e.g., SPREC)
From extraction to shipping and sample analysis, all data captured and displayed in patient-centered research records that include additional clinical and medical legacy data
Phenotypic context derived via interfaces within other documentation systems (e.g., hospital information systems, tumor documentation systems, etc.), providing a database with data to support downstream research
•
•
•
Precision oncology
Support for precision oncology needs from molecule to market, including:
•
•
•
•
•
CDx strategy & development
Global multi-omic sequencing capabilities (including China)
Genomic registry/extension study capabilities
Global, blended, multi-disciplinary teams to support research project needs
Bioinformatics services for subpopulation stratification
